impact of recession on your business
Dry Age-Related Macular Degeneration Market

Dry Age-Related Macular Degeneration Market by Stages (Early AMD, Intermediate AMD, Late AMD), by End User (Hospitals & Clinics, Diagnostic Centers, Academic Research Institutes, Others), by Age Group (Above 40 Years, Above 60 Years, Above 75 Years), by Diagnosis & Treatment (Treatment, Diagnosis), by Route of Administration (Oral, Injectables), by Region, and Global Forecast 2022-2028

Report Id: SNS/HC/2627 | July 2022 | Region: Global | 129 Pages

Report Scope & Overview:

The Dry Age-Related Macular Degeneration Market Size was valued at USD 10.28 billion in 2021 and is expected to reach USD 17.87 billion by 2028, and grow at a CAGR of  8.22% over the forecast period 2022-2028.

Dry macular degeneration and wet macular degeneration are the two types of age-related macular degeneration (AMD). Wet (neovascular) AMD can develop from neovascular macular degeneration, which is characterised by blood vessels developing under the retina and leaking. Dry-type occurs more commonly, while it progresses more slowly over time. In general, moist-type tends to cause a quick change in eyesight, ending in significant vision loss.

Dry Age-Related Macular Degeneration Market

The growing elderly population and increasing prevalence of age-related macular degeneration, as well as the development of novel dry AMD treatment approaches and an increasing number of clinical trials focused on dry AMD, are driving the global expansion of the dry AMD market. Other factors, such as rising healthcare costs, are expected to support market growth. The high number of failed clinical studies for dry AMD medicines, on the other hand, may limit market growth to some extent.



  • Geriatric Population Growth and the Prevalence of Dry Age-Related Macular Degeneration

  • Comprehensive and comparable estimates of each country's health spending are a critical input for health policy and planning, and are required to achieve national and international health goals.


  • Several medications for AMD treatment have failed to meet FDA accuracy standards.

  • Such unsuccessful clinical trials and rigorous regulations for dry AMD treatments may limit market expansion in the projected term.


The COVID-19 pandemic has had a severe impact on the dry age-related macular degeneration AMD market, as people are unable to visit ophthalmologists, reducing the overall number of patient visits. Furthermore, due to the intimate physical nature of the work, ophthalmologists themselves are at danger. Delays in diagnosis may also have negative consequences for patients, such as the development of dry AMD to advanced wet AMD. However, specialists advise people with dry AMD to continue home monitoring and make healthy lifestyle choices. Telehealth is widely used for virtual consultations with doctors. The supply chain for vitamin and zinc supplements advised for dry AMD is also impacted.

The increasing demand for supplements to improve immunity to fight coronavirus is not being met, which may have a harmful effect on individuals with dry AMD. However, companies are ramping up production, and with COVID-19 conditions easing in various nations, a return to normalcy supply and demand is likely soon.

The different governments imposed certain COVID-19-related limitations in order to control the spread of COVID-19. Travel restrictions and stay-at-home orders produced specific limitations that impacted the laboratory staff's capacity to do their tasks and perhaps disrupted the supply chain appropriately. Other possible consequences include a delay in project delivery timeframes and the storage of samples for an extended period of time due to the delay. Fear among lab personnel, as well as a lack of professionals, may impede research progress. However, because there is less human-to-human interaction in non-clinical research, the impact is likely to be minimal.

Because of the growing number of AMD patients at this stage, early-stage age-related macular degeneration has the second largest market share. There is no visual loss in early-stage AMD, which is identified by the development of medium-sized drusen beneath the retina. Drusen (yellow pigments) are amorphous debris accumulations near the basement membrane of the retinal pigment epithelium. The appearance of multiple medium-sized drusen or at least one big drusen, as well as noncentral geographic atrophy, characterises the intermediate stage of AMD. The appearance of multiple medium-sized drusen or at least one big drusen, as well as noncentral geographic atrophy, characterises the intermediate stage of AMD. The market is divided into three age groups: those aged 75 and up, those aged 60 and up, and those aged 40 and up. The above 75 years category accounts for the majority of the market and is expected to grow at a 7.49 percent CAGR from 2021 to 2028. Adults over the age of 40 are more likely to suffer vision issues, and typical changes in the eye's focusing ability, known as presbyopia, continue to worsen with age. Due to chronic, systemic illnesses such as diabetes, a family history of glaucoma, and health issues connected to excessive cholesterol, thyroid, or depression, this age group is especially vulnerable to dry AMD. Adults over the age of 60 may begin to show indicators of age-related issues that may lead to visual loss.

AMD is becoming more common in those over the age of 60, owing to various eye problems such as cataracts, dry eye, diabetic retinopathy, and glaucoma.

Due to the increasing prevalence of AMD in persons over the age of 75, as well as other dry age-related factors, this category dominates the global dry age-related macular degeneration market by age group. In 2021, Ithada had a market share of 45.29 percent. The dry age-related macular degeneration AMD market is divided into two categories: therapy and diagnostic. Nutrition therapy and telescopic lens implant are also options for treatment. Antioxidants and others are subcategories of nutrition treatment. Vitamins, zinc, copper, omega-3 fatty acids, and other antioxidants are also classified. The diagnosis segment is divided into optical coherence tomography, fluorescein angiography, preliminary test, and others. Nutrition therapy will have the biggest market share of 90.92 percent in 2021, owing to increasing trends, numerous medications in the pipeline, and the utilisation of novel treatment modalities.

Furthermore, the rising frequency of eye problems is expected to drive the worldwide dry age-related macular degeneration market during the forecast period. OCT offers a cross-sectional image of the eye that is used to assess the thickness of the macula and fluid leaking in the retina. A machine scans the retina, producing incredibly detailed images of the retina and macula. Based on the type of diagnosis, optical coherence tomography (OCT), a type of imaging that employs light to create images, has the biggest market share.

The market is divided into oral and injectables based on route of administration. The oral route, which is mostly used to treat age-related macular degeneration, has the greatest dry age-related macular degeneration AMD market share of 64.32 percent in 2021.

The key preventive treatment that can postpone the progression of eyesight loss is nutrition therapy. Dry age-related macular degeneration is treated with zinc, copper, beta-carotenoids, and other antioxidants. Because it was used in the majority of known clinical research, this method of administration has the biggest market share.

Injectables such as intravitreal and subretinal are the most often used therapy options for dry age-related macular degeneration. The currently active clinical trials for pegcetacoplan and Zimura are among the therapeutic alternatives for dry AMD delivered via this route. Small clinical trials have revealed that stem cells have no unanticipated side effects.


Santen Pharmaceuticals Inc., Ocumension Therapeutics Co. Ltd, Iveric Bio, Eyestem Research Pvt Ltd, Allergan plc, Bausch Health, Belite Bio Inc., Kubota Vision Inc., Alimera Science Inc., Phio Pharmaceuticals Corp,Yuyang DNU Co., Ltd, Stealth Biotherapeutics Inc.


by Stages

  • Early AMD

  • Intermediate AMD

  • Late AMD

by End User

  • Hospitals & Clinics

  • Diagnostic Centers

  • Academic Research Institutes

  • Others

by Age Group

  • Above 40 Years

  • Above 60 Years

  • Above 75 Years

by Diagnosis & Treatment

  • Treatment

  • Diagnosis

by Route of Administration

  • Oral

  • Injectables

Dry Age-Related Macular Degeneration Market


The Association for Research in Vision and Ophthalmology 2021 did a study between 2021 and 2028 and concluded that dry AMD had the highest disease burden with a 16.3 percent prevalence over the 6 years compared to wet AMD, diabetic macular edoema, diabetic retinopathy, and other indications.  Furthermore, rising government initiatives and financing are boosting the dry age-related macular degeneration market in North America.

Europe has the second biggest market share due to an ageing population and a growing patient population.

Furthermore, improving government initiatives, expanding healthcare frameworks, and rising demand for technologically novel therapy are propelling the dry age-related macular degeneration market in Europe forward.

The Asia-Pacific region is the fastest-growing market for age-related macular degeneration, with numerous new firms emerging at a rapid pace. Furthermore, the increased frequency of eye ailments, rising healthcare spending, and multinational corporations expanding into developing countries and establishing operational bases are expected to boost the growth of the dry age-related macular degeneration AMD market. According to the WHO, 90 percent of all visually impaired people lived in underdeveloped Asia-Pacific countries. Furthermore, due to the rapid expansion of healthcare infrastructure in these regions and the increasing demand for improved healthcare services, India and China are key contributors to market growth.

The rest of the world is predicted to grow slowly due to inadequate access and affordability of healthcare among the population. This region is divided into three parts: the Middle East, Africa, and Latin America. The growing healthcare infrastructure and healthcare expenditure in the Middle East are driving the expansion of the dry age-related macular degeneration AMD market.


  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • south Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America


Dry Age-Related Macular Degeneration Market Report Scope
Report Attributes Details
Market Size in 2021 US$ 10.28 Billion
Market Size by 2028 US$ 17.87 Billion
CAGR CAGR of 8.22% From 2022 to 2028
Base Year 2021
Forecast Period 2022-2028
Historical Data 2017-2020
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • by Stages (Early AMD, Intermediate AMD, Late AMD)
• by End User (Hospitals & Clinics, Diagnostic Centers, Academic Research Institutes, Others)
• by Age Group (Above 40 Years, Above 60 Years, Above 75 Years)
• by Diagnosis & Treatment (Treatment, Diagnosis)
• by Route of Administration (Oral, Injectables)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Santen Pharmaceuticals Inc., Ocumension Therapeutics Co. Ltd, Iveric Bio, Eyestem Research Pvt Ltd, Allergan plc, Bausch Health, Belite Bio Inc., Kubota Vision Inc., Alimera Science Inc., Phio Pharmaceuticals Corp,Yuyang DNU Co., Ltd, Stealth Biotherapeutics Inc.
Key Drivers • Geriatric Population Growth and the Prevalence of Dry Age-Related Macular Degeneration.
RESTRAINTS • Several medications for AMD treatment have failed to meet FDA accuracy standards.

Frequently Asked Questions (FAQ) :

Table of Contents


1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions


2. Research Methodology


3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges


4. Impact Analysis

4.1 COVID 19 Impact Analysis


5. Value Chain Analysis


6. Porter’s 5 forces model


7.  PEST Analysis


8.Global Dry Age-Related Macular Degeneration Market, by End User

8.1 Hospitals & Clinics

8.2 Diagnostic Centers

8.3 Academic Research Institutes

8.4 Others


9.Global Dry Age-Related Macular Degeneration Market, by Age Group

9.1 Above 40 Years

9.2 Above 60 Years

9.3 Above 75 Years


10.Global Dry Age-Related Macular Degeneration Market, by Route of Administration

10.1 Oral

10.2 Injectables


11.Global Dry Age-Related Macular Degeneration Market, by Stages

11.1 Early AMD

11.2 Intermediate AMD

11.3 Late AMD


12.Global Dry Age-Related Macular Degeneration Market, by Diagnosis & Treatment

12.1 Treatment

12.2 Diagnosis


13. Regional Analysis

13.1 Introduction

13.2 North America

13.2.1 USA

13.2.2 Canada

13.2.3 Mexico

13.3 Europe

13.3.1 Germany

13.3.2 UK

13.3.3 France

13.3.4 Italy

13.3.5 Spain

13.3.6 The Netherlands

13.3.7 Rest of Europe

13.4 Asia-Pacific

13.4.1 Japan

13.4.2 South Korea

13.4.3 China

13.4.4 India

13.4.5 Australia

13.4.6 Rest of Asia-Pacific

13.5 The Middle East & Africa

13.5.1 Israel

13.5.2 UAE

13.5.3 South Africa

13.5.4 Rest

13.6 Latin America

13.6.1 Brazil

13.6.2 Argentina

13.6.3 Rest of Latin America


14.Company Profiles

 14.1 Santen Pharmaceuticals Inc.

14.1.1 Financial

14.1.2 Products/ Services Offered

14.1.3 SWOT Analysis

14.1.4 The SNS view

14.2 Ocumension Therapeutics Co. Ltd

14.3 Iveric Bio

14.4 Eyestem Research Pvt Ltd

14.5 Allergan plc

14.6 Bausch Health

14.7 Belite Bio Inc.

14.8 Kubota Vision Inc.

14.9 Alimera Science Inc.

14.10 Phio Pharmaceuticals Corp


15. Competitive Landscape

15.1 Competitive Benchmarking

15.2 Market Share analysis

15.3 Recent Developments


16. Conclusion


An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of a good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach a stage wherein we can provide our clients best and most accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.


The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research as the name suggests is a research process wherein, we collect data through readily available information. In this process, we use various paid and unpaid databases to which our team has access and gather data through the same. This includes examining listed companies’ annual reports, Journals, SEC filling, etc. Apart from this, our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various universities as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content-specific facts that can be sued to solve specific problems. Since the collected data is fresh and first-hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply sides of the industry to make sure we land an accurate judgment and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses, and observation of on-field participants. The below-mentioned chart should give a better understanding of part 1 of the primary interview.

Part 2: In this part of the primary research the data collected via secondary research and part 1 of the primary research is validated with the interviews with individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence center, our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real-time.

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but is not limited to getting rid of the many typos, duplication of numbers, or missing any important information. The people involved in this process include technical content writers, research heads, and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.